NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
88 hedge funds and large institutions have $1.12B invested in NGM Biopharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 12 closing their positions.
107% more capital invested
Capital invested by funds: $543M → $1.12B (+$580M)
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
9% more funds holding
Funds holding: 81 → 88 (+7)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.78M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.62M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.27M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.14M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.41M |
| 2 |
Renaissance Technologies
New York
|
-$1.31M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.1M |
| 4 |
Two Sigma Investments
New York
|
-$788K |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$763K |
NGM Hedge Fund Activity: Q4 2020 in Review
88 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2020, worth a combined $1.12B — up 107% from $543M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NGM positions and 12 closed out — a net gain of 8 holders — while 26 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.78M. The largest seller was Bank of America, cutting an estimated $1.41M.
- 88 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2020, up from 81 in Q3 2020.
- Funds reported $1.12B of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2020, up 107% quarter-over-quarter.
- 20 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2020 and 12 closed out, a net change of +8 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Vanguard Group, an estimated $6.78M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2020 was Bank of America, an estimated $1.41M sold.
Based on aggregated 13F filings for Q4 2020.